丹黄祛瘀胶囊联合阿奇霉素对慢性盆腔炎患者血液流变学和血清炎症因子的影响

摘要 目的：观察阿奇霉素联合丹黄祛瘀胶囊在慢性盆腔炎患者中的应用价值。方法：研究病例选自2019年6月至2021年6月期间我院收治的慢性盆腔炎患者127例,采用随机数字表法将符合要求的患者分为对照组（63例,阿奇霉素治疗）和观察组（64例,丹黄祛瘀胶囊联合阿奇霉素治疗）,两组均治疗2周。对比两组疗效、临床症状消失时间、血液流变学和血清炎症因子变化情况,观察两组不良反应的发生情况,并作记录。结果：观察组临床总有效率高于对照组（P<0.05）。观察组的腰骶胀痛、下腹疼痛、带下异常等症状消失时间短于对照组（P<0.05）。观察组治疗2周后的白介素-6（IL-6）、白介素-1β（IL-1β）、C反应蛋白（CRP）低于对照组（P<0.05）。观察组治疗2周后的全血高切黏度、全血低切黏度、纤维蛋白原及红细胞沉降率低于对照组（P<0.05）。两组患者的不良反应发生率组间对比无统计学差异（P>0.05）。结论：慢性盆腔炎在阿奇霉素治疗基础上联合丹黄祛瘀胶囊,症状得到明显缓解,同时还可改善机体血液流变学和炎症因子水平,临床应用价值较好。     

木丹颗粒联合羟苯磺酸钙胶囊对糖尿病周围神经病变患者神经传导速度、血液流变学和氧化应激的影响

摘要 目的：探讨木丹颗粒联合羟苯磺酸钙胶囊对糖尿病周围神经病变（DPN）患者神经传导速度、血液流变学和氧化应激的影响。方法：选取2018年9月~2020年8月期间我院收治的120例DPN患者。按照随机数字表法分为观察组（60例,木丹颗粒联合羟苯磺酸钙胶囊治疗）和对照组（60例,羟苯磺酸钙胶囊治疗）,均治疗8周。对比两组疗效、神经传导速度、血液流变学和氧化应激,记录两组不良反应发生情况。结果：观察组的临床总有效率高于对照组（P<0.05）。观察组治疗后正中神经、腓总神经的运动传导速度（MNCV）和感觉传导速度（SNCV）均较治疗前升高,且高于对照组（P<0.05）。两组治疗后全血低切黏度、全血高切黏度、纤维蛋白原、血浆黏度均较治疗前降低,且观察组低于对照组（P<0.05）。两组治疗后丙二醛（MDA）较治疗前降低,超氧化物歧化酶（SOD）较治疗前升高（P<0.05）,且观察组MDA较对照组低,SOD较对照组高（P<0.05）。两组不良反应发生率对比无明显差异（P>0.05）。结论：木丹颗粒联合羟苯磺酸钙胶囊治疗DPN患者疗效确切,可提高患者神经传导速度和抗氧化应激能力,改善血液流变学状态,安全可靠。     

血栓通胶囊辅助治疗进展性脑梗死的疗效及对患者神经功能、血液流变学和血清炎性因子的影响

摘要 目的：探讨血栓通胶囊辅助治疗进展性脑梗死的疗效及对患者神经功能、血液流变学和血清炎性因子的影响。方法：选择114例进展性脑梗死患者,随机分为对照组57例和观察组57例,对照组给予常规治疗,观察组在对照组的基础上联合血栓通胶囊治疗,比较两组疗效、神经功能、血液流变学、炎性因子及不良反应。结果：治疗1个月后观察组的临床总有效率较对照组高（P<0.05）。两组治疗1个月后全血黏度、血浆黏度、红细胞沉降率下降,且观察组低于对照组（P<0.05）。两组治疗1个月后白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）水平下降,且观察组低于对照组（P<0.05）。两组治疗1个月后神经功能指标S-100β蛋白（S-100β）、神经元特异性烯醇化酶（NSE）水平、神经功能缺损卒中量表（NIHSS）评分下降,且观察组低于对照组（P<0.05）。两组药物相关不良反应的发生率比较无差异（P>0.05）。结论：血栓通胶囊辅助治疗进展性脑梗死,可有效改善神经功能、血液流变学,降低机体炎性反应,可获得较好的治疗效果。     

心可舒胶囊联合氯吡格雷对冠心病心绞痛患者血管内皮功能、血液流变学及炎症因子的影响

摘要 目的：观察心可舒胶囊联合氯吡格雷对冠心病心绞痛患者血管内皮功能、血液流变学及炎症因子的影响。方法：选取2020年3月~2021年10月期间中国人民解放军东部战区总医院收治的92例冠心病心绞痛患者。按照信封抽签法分为对照组（46例）和观察组（46例）。对照组患者接受氯吡格雷治疗,观察组接受心可舒胶囊联合氯吡格雷治疗,对比两组疗效、血管内皮功能、血液流变学、炎症因子、心绞痛发作频率、硝酸甘油用量、心绞痛发作持续时间及不良反应。结果：与对照组相比,观察组治疗1个月后的临床总有效率更高（P<0.05）。与对照组相比,观察组治疗1个月后全血黏度、血浆比黏度、红细胞聚集指数更低（P<0.05）。与对照组相比,观察组治疗1个月后内皮素-1（ET-1）更低,一氧化氮（NO）更高（P<0.05）。与对照组相比,观察组治疗1个月后白介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、单核细胞趋化蛋白-1（MCP-1）更低（P<0.05）。与对照组相比,观察组治疗1个月后心绞痛发作频率、硝酸甘油用量更少,心绞痛发作持续时间更短（P<0.05）。两组不良反应发生率组间对比无统计学差异（P>0.05）。结论：心可舒胶囊联合氯吡格雷可改善冠心病心绞痛患者临床症状,改善血管内皮功能和血液流变学,降低炎症因子水平,效果显著。     

坤复康片联合阿莫西林克拉维酸钾对慢性盆腔炎患者血液流变学、红细胞免疫功能和炎症因子的影响

摘要 目的：探讨坤复康片联合阿莫西林克拉维酸钾对慢性盆腔炎患者血液流变学、红细胞免疫功能和炎症因子的影响。方法：采用随机数字表法将我院2021年4月~2022年4月期间收治的98例慢性盆腔炎患者分为对照组（阿莫西林克拉维酸钾干混悬剂治疗,n=49）和研究组（坤复康片联合阿莫西林克拉维酸钾干混悬剂治疗,n=49）。对比两组症状好转时间、血液流变学、红细胞免疫功能和炎症因子水平,观察两种用药方案的安全性。结果：研究组的下腹疼痛、腰骶疼痛、白带量多、经期量多等临床症状好转时间均短于对照组（P<0.05）。研究组治疗14 d后全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原水平低于对照组（P<0.05）。研究组治疗14 d后血红细胞C3b受体花环率（RBC-C3bRR）高于对照组,免疫复合物花环率（RBC-ICR）低于对照组（P<0.05）。研究组治疗14 d后血清C反应蛋白（CRP）、白细胞介素-17（IL-17）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：坤复康片联合阿莫西林克拉维酸钾可通过改善慢性盆腔炎患者的血液流变学、炎症因子、红细胞免疫功能来改善临床症状,具有较好的临床疗效。     

抗妇炎胶囊联合阿莫西林克拉维酸钾片对慢性盆腔炎患者炎性因子、血液流变学和子宫动脉血流动力参数的影响

摘要 目的：观察抗妇炎胶囊联合阿莫西林克拉维酸钾片对慢性盆腔炎患者炎性因子、血液流变学和子宫动脉血流动力参数的影响。方法：采用随机数字表法将西安市人民医院2020年3月~2021年10月期间收治的慢性盆腔炎（n=112）患者分为对照组（阿莫西林克拉维酸钾片治疗,n=56）和研究组（抗妇炎胶囊联合阿莫西林克拉维酸钾片治疗,n=56）,两组患者均治疗14d后,观察两组疗效、不良反应发生情况和临床症状缓解情况,对比两组治疗前、治疗14d后的炎性因子、血液流变学和子宫动脉血流动力参数变化情况。结果：研究组的临床总有效率高于对照组（P<0.05）。研究组的下腹疼痛、白带异常、腰骶骨疼痛、经期量多症状消失时间均短于对照组（P<0.05）。研究组治疗14d后血清单核细胞趋化蛋白1（MCP-1）、白介素-21（IL-21）、C反应蛋白（CRP）水平低于对照组,白介素-2（IL-2）水平高于对照组（P<0.05）。研究组治疗14 d后全血黏度低切、血浆黏度、全血黏度高切低于对照组（P<0.05）。研究组治疗14 d后阻力指数（RI）、搏动指数（PI）低于对照组,最大血流速度（Vmax）高于对照组（P<0.05）。两组不良反应发生率,组间对比无统计学差异（P>0.05）。结论：阿莫西林克拉维酸钾片联合抗妇炎胶囊治疗慢性盆腔炎,可降低炎性因子水平,改善血液流变学和子宫动脉血流动力参数,促进临床症状改善,效果显著。     

补肺活血胶囊联合喘可治注射液对慢性阻塞性肺疾病稳定期患者肺功能、 血气指标以及血液流变学的影响

摘要 目的：探讨补肺活血胶囊联合喘可治注射液对慢性阻塞性肺疾病（COPD）稳定期患者肺功能、血气指标以及血液流变学的影响。方法：选取我院于2017年8月到2019年12月期间接收的126例COPD稳定期患者,按照随机数字表法将患者分为对照组（n=63）和研究组（n=63）,对照组给予静注喘可治注射液,研究组在对照组的基础上联合补肺活血胶囊治疗,均治疗12周。比较两组患者疗效、肺功能、血气指标以及血液流变学,记录两组治疗期间不良反应情况。结果：治疗12周后,研究组的临床总有效率84.13%（53/63）高于对照组66.67%（42/63）（P<0.05）。两组第1秒用力呼气容积（FEV₁）、用力肺活量（FVC）、FEV₁/FVC均较治疗前升高,且研究组高于对照组（P<0.05）。两组治疗12周后动脉氧分压（PaO₂）较治疗前升高,且研究组高于对照组（P<0.05）;两组治疗12周后动脉二氧化碳分压（PaCO₂）较治疗前降低,且研究组低于对照组（P<0.05）。两组血浆黏度、纤维蛋白原、全血黏度水平均下降,研究组较对照组低（P<0.05）。两组不良反应发生率比较无差异(P>0.05)。结论：COPD稳定期患者在喘可治注射液的基础上联合补肺活血胶囊治疗,血气指标、肺功能以及血液流变学可得到显著改善,且用药安全性好,疗效较好。     

溶栓胶囊联合丁苯酞软胶囊对脑梗死恢复期患者血液流变学、脑血流动力学和神经因子的影响

摘要 目的：探讨溶栓胶囊联合丁苯酞软胶囊对脑梗死恢复期患者血液流变学、脑血流动力学和神经因子的影响。方法：选取2021年1月-2022年1月期间长治医学院附属和平医院收治的100例脑梗死恢复期患者,按照随机数字表法分为研究组（50例）和对照组（50例）,对照组接受丁苯酞软胶囊治疗,研究组接受溶栓胶囊联合丁苯酞软胶囊治疗。对比两组疗效、血液流变学、脑血流动力学、神经因子和不良反应发生情况。结果：研究组90.00%的临床总有效率高于对照组72.00%（P<0.05）。治疗20 d后,两组美国国立卫生院神经功能缺损评分（NIHSS）评分下降,Barthel指数（BI）评分升高,且研究组改善幅度大于对照组（P<0.05）。治疗20 d后,两组全血粘度、血浆粘度、血沉（ESR）、纤维蛋白原（FIB）和红细胞压积（HCT）均下降,且研究组低于对照组（P<0.05）。治疗20 d后,两组平均血流速度（Vm）升高,搏动指数（PI）及阻力指数（RI）均下降,且研究组改善幅度大于对照组（P<0.05）。治疗20 d后,两组神经元特异性烯醇化酶（NSE）下降,神经生长因子（NGF）、神经营养因子（BDNF）升高,且研究组改善幅度大于对照组（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：溶栓胶囊联合丁苯酞软胶囊可有效改善脑梗死恢复期患者血液流变学、脑血流动力学,促进神经功能恢复,提高生活活动能力,效果显著。     

风湿祛痛胶囊联合塞来昔布胶囊治疗强直性脊柱炎的疗效及对血液流变学和血清炎性因子的影响

摘要 目的：探讨强直性脊柱炎（AS）患者经风湿祛痛胶囊联合塞来昔布胶囊治疗后的疗效及对血液流变学和血清炎性因子的影响。方法：选取2014年8月-2021年12月在联勤保障部队第九八三医院治疗的80例AS患者。按照随机数字表法分为对照组（常规治疗及塞来昔布胶囊治疗，40例）和研究组（常规治疗及风湿祛痛胶囊联合塞来昔布胶囊治疗，40例），两组患者均治疗8周。对比两组血液流变学指标、血清炎性因子指标、视觉模拟评分法（VAS）评分、C反应蛋白（CRP）、巴氏强直性脊柱炎疾病活动指数（BASDAI）评分、红细胞沉降率（ESR），同时记录两组治疗期间不良反应发生情况。结果：研究组治疗8周后BASDAI、VAS评分低于对照组（P<0.05）。研究组治疗8周后CRP、ESR低于对照组（P<0.05）。研究组治疗8周后全血高切黏度、血浆黏度、全血低切黏度、红细胞压积低于对照组（P<0.05）。研究组治疗8周后白介素-23（IL-23）、肿瘤坏死因子-α（TNF-α）、白介素-1β（IL-1β）均低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：风湿祛痛胶囊联合塞来昔布胶囊治疗AS，可有效缓解患者的临床症状，抑制疾病进展，可能与调节血液流变学、降低炎性因子水平有关。     

冠心舒通胶囊联合尼可地尔对冠心病稳定型心绞痛心血瘀阻型患者心功能、血液流变学和炎症因子的影响

摘要 目的：观察冠心舒通胶囊联合尼可地尔在冠心病稳定型心绞痛心血瘀阻型患者中的应用价值。方法：根据随机数字表法,将广州中医药大学附属重庆北碚中医院2021年1月~2021年12月期间收治的冠心病稳定型心绞痛患者108例分为对照组（尼可地尔治疗,n=54）和观察组（冠心舒通胶囊联合尼可地尔治疗,n=54）。对比两组临床疗效、炎症因子水平、硝酸甘油片用量、西雅图心绞痛量表评分、中医证候总积分、血液流变学指标、心功能、不良反应。结果：治疗后,观察组的临床总有效率高于对照组（P<0.05）。治疗后,观察组西雅图心绞痛量表评分高于对照组,硝酸甘油片使用量少于对照组,中医证候总积分低于对照组（P<0.05）。治疗后,观察组左心室射血分数（LVEF）、心脏指数（CI）、左心室短轴缩短分数（LVFS）高于对照组（P<0.05）。治疗后,观察组全血黏度、血浆黏度及红细胞比容低于对照组（P<0.05）。治疗后,观察组白介素-1（IL-1）、肿瘤坏死因子-α（TNF-α）、髓过氧化物酶（MPO）、C反应蛋白（CRP）水平低于对照组（P<0.05）。两组不良反应发生率组间对比,无统计学差异（P>0.05）。结论：尼可地尔与冠心舒通胶囊联合治疗可提高冠心病稳定型心绞痛心血瘀阻型患者的治疗效果,改善其心功能和血液流变学,降低炎症因子水平,具有一定临床应用价值。     

Profiling Inflammatory Responses with Microfluidic Immunoblotting

Rapid profiling of signaling pathways has been a long sought after goal in biological sciences and clinical medicine. To understand these signaling pathways, their protein components must be profiled. The protein components of signaling pathways are typically profiled with protein immunoblotting. Protein immunoblotting is a powerful technique but has several limitations including the large sample requirements, high amounts of antibody, and limitations in assay throughput. To overcome some of these limitations, we have designed a microfluidic protein immunoblotting device to profile multiple signaling pathways simultaneously. We show the utility of this approach by profiling inflammatory signaling pathways (NFκB, JAK-STAT, and MAPK) in cell models and human samples. The microfluidic immunoblotting device can profile proteins and protein modifications with 5380-fold less antibody compared to traditional protein immunoblotting. Additionally, this microfluidic device interfaces with commonly available immunoblotting equipment, has the ability to multiplex, and is compatible with several protein detection methodologies. We anticipate that this microfluidic device will complement existing techniques and is well suited for life science applications.     

Cytomegalovirus Infection in Inflammatory Bowel Disease Is Not Associated with Worsening of Intestinal Inflammatory Activity

Background

Cytomegalovirus is highly prevalent virus and usually occurs in immunocompromised patients. The pathophysiology and treatment of inflammatory bowel disease often induce a state of immunosuppression. Because this, there are still doubts and controversies about the relationship between inflammatory bowel disease and cytomegalovirus.

Aim

Evaluate the frequency of cytomegalovirus in patients with inflammatory bowel disease and identify correlations.

Methods

Patients with inflammatory bowel disease underwent an interview, review of records and collection of blood and fecal samples. The search for cytomegalovirus was performed by IgG and IgM blood serology, by real-time PCR in the blood and by qualitative PCR in feces. Results were correlated with red blood cell levels, C-reactive protein levels, erythrocyte sedimentation rates and fecal calprotectin levels for each patient.

Results

Among the 400 eligible patients, 249 had Crohn''s disease, and 151 had ulcerative colitis. In the group of Crohn''s disease, 67 of the patients had moderate or severe disease, but 126 patients presented with active disease, based on the evaluation of the fecal calprotectin. In patients with ulcerative colitis, only 21 patients had moderate disease, but 76 patients presented with active disease, based on the evaluation of the fecal calprotectin. A large majority of patients had positive CMV IgG. Overall, 10 patients had positive CMV IgM, and 9 patients had a positive qualitative detection of CMV DNA by PCR in the feces. All 400 patients returned negative results after the quantitative detection of CMV DNA in blood by real-time PCR. Analyzing the 19 patients with active infections, we only found that such an association occurred with the use of combined therapy (anti-TNF-alpha + azathioprine)

Conclusion

The findings show that latent cytomegalovirus infections are frequent and active cytomegalovirus infection is rare. We did not find any association between an active infection of CMV and inflammatory bowel disease activity.     

Inflammatory markers associated with abdominal aortic aneurysm

Purpose

Inflammation with leukocytic infiltration, degradation of extracellular matrix (ECM), and depletion of vascular smooth muscle cells (VSMC) are pathological hallmarks of abdominal aortic aneurysm (AAA). The aim of this study was to further evaluate relationships betweenAAAand inflammatory biomarkers, interleukin- 6 (IL-6), tumour necrosis factor-α (TNF-α), endothelin-1 (ET-1) and soluble urokinase-type plasminogen activator receptor (suPAR), by comparing levels in 65-year-old men with and without AAA at ultrasound screening.We also evaluated whether any biomarker can independently predict AAA at screening, and clarified potential correlations between aortic diameter and blood levels of these biomarkers.

Results

There were significant (p ? 0.05) differences between subjects with and without AAA for the following variables: p-leukocyte count (TLC) (p<0.001), p-homocysteine (p<0.001), p-TNF-α (p = 0.023), p-IL-6 (p<0.001), p-ET-1 (p = 0.002), p-suPAR (p<0.001), ankle brachial index (ABI) (p<0.001), plasma (p)-creatinine (p = 0.049), p-total cholesterol (p<0.001), p-high density lipoprotein (HDL) (p<0.001) and low density lipoprotein (LDL) cholesterol (p = 0.001), smoking habits (p<0.001), and use of antihypertensive (p<0.001) and lipid-lowering (p = 0.001) drugs. When the above variables were stepwise excluded in a logistic regression model, only p-IL-6 (p = 0.002), p-homocysteine (p = 0.015), p-HDL (p = 0.004), ABI in the right (p = 0.005) and left (p = 0.094) leg, smoking habits (p = 0.003), and antihypertensive drug use (p = 0.045), differed between groups. Significant correlations with aortic diameter existed for p-TNF-α (p = 0.028), p-IL-6 (p<0.001), p-ET-1 (p = 0.002) and p-suPAR (p<0.001) in the entire study population, and for p-TNF-α (p = 0.023), p-ET-1 (p = 0.009) and p-suPAR (p = 0.001) among men with AAA.

Conclusions

Several inflammatory biomarkers were significantly elevated and correlated with aortic diameter among 65-year old men with AAA at ultrasound screening. IL-6, homocysteine and use of antihypertensive medication remained elevated in the logistic regression model, together with known risk markers for AAA such as smoking and signs of atherosclerosis.

     

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Nasopharyngeal colonization by Streptococcus pneumoniae is a prerequisite to invasion to the lungs or bloodstream¹. This organism is capable of colonizing the mucosal surface of the nasopharynx, where it can reside, multiply and eventually overcome host defences to invade to other tissues of the host. Establishment of an infection in the normally lower respiratory tract results in pneumonia. Alternatively, the bacteria can disseminate into the bloodstream causing bacteraemia, which is associated with high mortality rates², or else lead directly to the development of pneumococcal meningitis. Understanding the kinetics of, and immune responses to, nasopharyngeal colonization is an important aspect of S. pneumoniae infection models.Our mouse model of intranasal colonization is adapted from human models³ and has been used by multiple research groups in the study of host-pathogen responses in the nasopharynx^4-7. In the first part of the model, we use a clinical isolate of S. pneumoniae to establish a self-limiting bacterial colonization that is similar to carriage events in human adults. The procedure detailed herein involves preparation of a bacterial inoculum, followed by the establishment of a colonization event through delivery of the inoculum via an intranasal route of administration. Resident macrophages are the predominant cell type in the nasopharynx during the steady state. Typically, there are few lymphocytes present in uninfected mice⁸, however mucosal colonization will lead to low- to high-grade inflammation (depending on the virulence of the bacterial species and strain) that will result in an immune response and the subsequent recruitment of host immune cells. These cells can be isolated by a lavage of the tracheal contents through the nares, and correlated to the density of colonization bacteria to better understand the kinetics of the infection.     

Inflammatory and Immunological parameters in adults with Down syndrome

Background  

The increase in life expectancy within the general population has resulted in an increasing number of elderly adults, including patients with Down syndrome (DS), with a current life expectancy of about 50 years. We evaluate the parameters of humoral and cellular immune response, the quantitative expression of the regulator of calcineurin1 gene (RCAN1) and the production of cytokines. The study group consisted of adults DS (n = 24) and a control group with intellectual disability without Down syndrome (ID) (n = 21) and living in a similar environmental background. It was evaluated serology, immunophenotyping, the quantitative gene expression of RCAN1 and the production of cytokines.     

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor

Background: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine involved in certain inflammatory diseases including multiple sclerosis (MS), rheumatoid arthritis (RA), and Crohn’s disease. The anti-TNF-α treatments used for RA may be associated with inflammatory demyelinating events affecting the central nervous system and may possibly aggravate known MS. Objective: We report here three new cases of inflammatory demyelinating events of the central nervous system following treatment with anti-TNF-α. Results: The neurological symptoms appeared on average 5 months after initiation of the treatment. For all patients, the inflammatory process was confirmed by brain magnetic resonance imaging. The symptoms totally or partially regressed as soon as anti-TNF-α treatment was stopped except for one patient who developed clinically defined MS. Conclusions: Inflammatory demyelination of the central nervous system may be associated with the use of anti-TNF-α. Patients with rheumatoid arthritis treated with these treatments should benefit from a follow-up which includes brain MRI.